EveryBaby, an Irish health-tech company, said it intends to IPO in Hong Kong in the form of 18A in the future.

Dabriel Choi, CEO of EveryBaby, a health-tech company from Ireland, revealed at a media luncheon that the company plans to raise funds later this year, selling 20% of its shares to digital and healthcare investors in the United States. The company is eyeing a Hong Kong IPO in the form of 18A (for biotech companies without profits or revenue), but no timetable has been set yet. EveryBaby specializes in preventing premature births through analyzing cervical tissue, and is currently wholly owned by Dabriel Choi. He works in London, while the Asia-Pacific headquarters is in Hong Kong, due to the city's strong medical infrastructure and strategic location to help penetrate the Chinese market. Additionally, EveryBaby is developing the Middle East market and has an office in the United Arab Emirates. The Hong Kong Investment Promotion Agency (InvestHK) today held the 2025 Women's Health and Technology Forum, bringing together outstanding representatives from the government, academia, and the private sector to explore the relationship between technology and women's health. The forum and its media events covered topics such as policy initiatives, clinical research, and ecosystem development, attracting key stakeholders interested in developing the healthcare sector in Hong Kong.